HCW Biologics Price To Book vs. Shares Owned By Insiders

HCWB Stock  USD 0.45  0.04  9.76%   
Based on HCW Biologics' profitability indicators, HCW Biologics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess HCW Biologics' ability to earn profits and add value for shareholders. At present, HCW Biologics' Price To Sales Ratio is projected to decrease significantly based on the last few years of reporting. The current year's EV To Sales is expected to grow to 28.90, whereas Days Sales Outstanding is forecasted to decline to 162.25. At present, HCW Biologics' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 759 K, whereas Accumulated Other Comprehensive Income is projected to grow to (45.8 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.320.1972
Way Up
Slightly volatile
For HCW Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HCW Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HCW Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HCW Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HCW Biologics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.107
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.70)
Return On Equity
(3.44)
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

HCW Biologics Shares Owned By Insiders vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining HCW Biologics's current stock value. Our valuation model uses many indicators to compare HCW Biologics value to that of its competitors to determine the firm's financial worth.
HCW Biologics is rated # 3 in price to book category among its peers. It is one of the top stocks in shares owned by insiders category among its peers making about  18.68  of Shares Owned By Insiders per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HCW Biologics' earnings, one of the primary drivers of an investment's value.

HCW Shares Owned By Insiders vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

HCW Biologics

P/B

 = 

MV Per Share

BV Per Share

 = 
2.80 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

HCW Biologics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
52.30 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

HCW Shares Owned By Insiders Comparison

HCW Biologics is currently under evaluation in shares owned by insiders category among its peers.

HCW Biologics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in HCW Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HCW Biologics will eventually generate negative long term returns. The profitability progress is the general direction of HCW Biologics' change in net profit over the period of time. It can combine multiple indicators of HCW Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-48.2 M-45.8 M
Net Interest Income-378.9 K-360 K
Interest Income581.2 K610.2 K
Operating Income-25.7 M-24.4 M
Net Loss-19.7 M-18.7 M
Income Before Tax-25 M-23.7 M
Total Other Income Expense Net722.9 K759 K
Net Loss-13.4 M-14.1 M
Net Loss-25 M-23.7 M
Income Tax Expense(4.00)(4.20)
Change To Netincome1.5 M1.6 M
Net Loss(0.70)(0.73)
Income Quality 0.90  1.14 
Net Income Per E B T 1.14  1.08 

HCW Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on HCW Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HCW Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HCW Biologics' important profitability drivers and their relationship over time.

Use HCW Biologics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HCW Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HCW Biologics will appreciate offsetting losses from the drop in the long position's value.

HCW Biologics Pair Trading

HCW Biologics Pair Trading Analysis

The ability to find closely correlated positions to HCW Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HCW Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HCW Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HCW Biologics to buy it.
The correlation of HCW Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HCW Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HCW Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HCW Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your HCW Biologics position

In addition to having HCW Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run High Yield ETFs Thematic Idea Now

High Yield ETFs
High Yield ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Yield ETFs theme has 106 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Yield ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
Check out Risk vs Return Analysis.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project HCW Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HCW Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HCW Biologics' income statement, its balance sheet, and the statement of cash flows.
Potential HCW Biologics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although HCW Biologics investors may work on each financial statement separately, they are all related. The changes in HCW Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on HCW Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.